期刊文献+

荣成市的心肌梗死后二级预防状况调查分析

The Investigation and Analyses About the Situation of Secondary Prevention after Myocardial Infarction in Rong- cheng City
暂未订购
导出
摘要 目的:了解近几年荣成市心肌梗死(MI)后的二级预防状况。方法:对荣成市3所二甲医院2000年1月1日~2001年12月31日和2003年1月1日~2004年12月31日住院确诊的MI病人,出院后3个月以上的有关情况分别于2002年3月、2005年3月进行了两次调查。结果:2002年共调查了247例病人,其中男性170人,占68.8%,年龄中位数为69岁,应用阿司匹林(ASA)、β-阻滞剂(BB)、血管紧张素转换酶抑制剂(ACEI)、他汀类降脂药(Statirts)的比率分别为78.1%、40.9%、47.7%、14.6%,总胆固醇达标率(指TC<4.68mmol/L)为8.5%,吸烟率为46.5%(男性)。2005年共调查了318例病人,其中男性223人,占70.1%,年龄中位数为72岁,应用ASA、BB、ACEI、Statins的比率分别81.4%、50.3%、52.5%、57.9%,TC达标率为13.5%,吸烟率为41.7%(男性)。结论:2005年荣成市MI后二级预防状况比较2002年有很大进步,但与2001年急性心肌梗死(AMI)诊断和治疗指南中关于MI后二级预防的要求还有很大差距。 Objective: To understanding the situation of secondary prevention after myocardial infarction in the recent years in coastal area.Methods: For the patients who have been accurately diagnosed myocardial infarction from Jan 1st 2000 to Dec 31st 2001 and from Jan 1st 2003 to Dec 31st 2004 in three hospitals in Rang Cheng City, the relative situation of the patients who have leaved hospital(over 3 months) was surveyed twice respectively in Feb 2002 and Feb 2005.Besults: 247 cases were surveyed in 2002, with 68.8% in male, and the intermediate age was 69, the rate of smoking was 46.5% (male), and the ratio of the application of Aspirin, β- Blockades, A CEI, Statins was respectively 78.1%, 40.9%, 47.7 % and 14.6%, and up to standard to rate of total cholesterol(TC 〈 4.68mmol/L) was 8.5%. 318 cases were surveyed in 2005, with 70.1% in male, and the intermediate age was 72, the rate of smoking was 41.7% (male), and the ratio of the application of Aspirin, β - Blockades, ACEI, Statios was respectively 81.4%, 50.3%, 52.5% and 57.9% ,and up to standard to rate of total cholesterol was 13.5%. Conclusion: Great progresses have been made in the secondary prevention after myocardial infarction in Rang Cheng City in 2005 in comparison with the year 2002,but there are.still great gap with the requirement of the diagnosis and treatment guide for the acute myocardial infarction established in 2001.
出处 《中国医药导刊》 2006年第1期30-31,33,共3页 Chinese Journal of Medicinal Guide
关键词 心肌梗死 二级预防 调查 myocardial infarction secondary prevention investigation
  • 相关文献

参考文献3

二级参考文献13

  • 1Scandinavian Simvastatin Survival Study Group. Ransonised trial of cholesterol lowering in 4444 subjects with coronary heart disease: The Scandinavian Simvastatin Survival Study(4S) . Lancet, 1994; 344;1383~ 1389.
  • 2Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995; 333(20): 1301 ~ 1307.
  • 3Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med, 1996;335:1001 ~ 1009?A.
  • 4The long - term intervention with Pravastatin in ischemic Disease (LIPID)Study Group. Prevention of cardiovascular events and death with pracastatin in patients with coronary heart disease and a broud range of initial cholesterol levels. N Engl J Med, 1998;339:1349 ~ 1357.
  • 5Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA, 1998;279; 1615 ~ 1622.
  • 6He Jiang, Gu DG, Reynolds K, et al.Serum Total and Lipoprotein Cholestrol Levels and Awareness, Treatment, and Control of Hypercholesterolemia in China. Circulation, 2004; 110: 405 ~ 411.
  • 7Adult Treatment Panel Ⅲ: Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA, 2001;285:2486~ 2497.
  • 8Heart Protection Study Collaborative Group. MRC. BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. Lancet, 2002;360: 7~ 22.
  • 9Nissen SE, Tuzcu E.M, Schoenhagen P, et al. Effect of intensive compared with moderate lipid- lowering therapy on progression of coronary atherosclerosis. JAMA, 2004; 291 (9): 107 1 ~ 1080.
  • 10Cannon CP, Braunwald E, McCabe CH,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004;350(15): 1495 ~ 1504.

共引文献5290

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部